SCHEMBL21823769

SCHEMBL21823769

O=Cc1csc(-c2ccc(Br)cc2F)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 1/20 0.48
MAPT P10636 3/20 0.42
ALDH1A1 P00352 3/20 0.42
CYP2A6 P11509 2/20 0.36
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
DGAT1 O75907 1/20 0.33
LMNA P02545 2/20 0.32
NMUR2 Q9GZQ4 1/20 0.32
PPARG P37231 1/20 0.32
GFER P55789 1/20 0.32
NCOA2 Q15596 1/20 0.32
NCOA1 Q15788 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
AR P10275 1/20 0.32
ERN1 O75460 1/20 0.31
S100A4 P26447 1/20 0.31
VSIR Q9H7M9 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC8 Q9BY41 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18003352 0.82 HTR2B (0.48) HTR2BMAPTALDH1A1NPC1RAB9A
SCHEMBL21823781 0.79 HTR2B (0.68) HTR2BMAPTALDH1A1NPC1RAB9A
SCHEMBL22696619 0.76 ALOX5AP (0.44) MAPTALDH1A1ALOX5APFEN1DGAT1
SCHEMBL18003787 0.75 MAPT (0.51) HTR2BMAPTALDH1A1LMNAAR
SCHEMBL17802307 0.74 ALDH1A1 (0.63) HTR2BMAPTALDH1A1MEN1NPC1
SCHEMBL18004023 0.73 HTR2B (0.48) HTR2BMAPTALDH1A1AR
SCHEMBL2561104 0.72 HTR2B (0.46) HTR2BMAPTALDH1A1CYP2A6HDAC1
SCHEMBL15330795 0.72 CYP2A6 (0.36) CYP2A6ALOX5APFEN1DGAT1NMUR2
SCHEMBL31129057 0.72 ALOX5AP (0.35) ALDH1A1CYP2A6ALOX5APFEN1DGAT1
SCHEMBL14980853 0.71 HTR2B (0.53) HTR2BMAPTALDH1A1ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3860994-B1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE UNIV BRITISH COLUMBIA (CA) 2024-08-14 EP disclosed
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2022-04-07 US disclosed
EP-3860994-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE The University of British Columbia (CA) 2021-08-11 EP disclosed
WO-2020069625-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2020-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use BRDT, CBFB, CREBBP HTR2B 2831/4885MAPT 1816/4885ALDH1A1 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.